The recent surge in capital into niche pharmaceutical companies, particularly those focusing on groundbreaking therapies and challenging drug development programs, has fueled what some are calling "High Roller Pharma." While the promise for game-changing treatments and impressive returns is certain, the connected risks are also considerable. Man… Read More